News
Regeneron and Inovio to aim immunotherapy at hard-to-treat b...
Regeneron is to collaborate with Inovio to investigate a three-way immunotherapy combination against glioblastoma multiforme (GBM), an aggressive and hard-to-treat brain tumour.
